Navigation Links
TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
Date:4/20/2011

BOSTON, April 20, 2011 /PRNewswire/ -- TEI Biosciences today announced that Yiannis Monovoukas, Ph.D., M.B.A., its Chairman, President and CEO, is an Ernst & Young Entrepreneur Of The Year® 2011 New England Award semifinalist. The program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.  Dr. Monovoukas was selected as a semifinalist by a panel of independent judges.  Award winners will be announced on 15 June 2011.

"It's a true honor to be in the company of such talented entrepreneurs, in such an innovative and dynamic part of the country.  This recognition reflects the exciting things we have accomplished at TEI, but we're even more enthusiastic about the opportunities that lie ahead," said Dr. Monovoukas.

The Ernst & Young Entrepreneur Of The Year Program celebrates its 25th anniversary this year and recognizes business leaders in more than 50 countries throughout the world.

About TEI Biosciences Inc.

A Boston-based, privately-held, leading biomedical company, TEI Biosciences has applied its expertise in regenerative medicine to develop and commercialize novel biologic devices for a broad spectrum of soft tissue repair and regeneration applications -- from dura, tendon and hernia repair to plastic and reconstructive surgery, and wound healing.

TEI sells its products directly and through partnerships with some of the world's major medical device companies.  TEI's marketed products include:

  • SurgiMend® for plastic & reconstructive surgery and abdominal wall reconstruction
  • SurgiMend® PRS for breast reconstruction
  • PriMatrix™ for skin wound management
  • PriMatrix™ Ag Antimicrobial for skin wound management
  • Durepair® for cranial dura repair (marketed by Medtronic)
  • Xenform™ for pelvic floor reconstruction (marketed by Boston Scientific)
  • TissueMend® for tendon augmentation (marketed by Stryker)

About Ernst & Young Entrepreneur Of The Year®

Ernst & Young Entrepreneur Of The Year® is the world's most prestigious business award for entrepreneurs. The award encourages entrepreneurial activity among those with potential, and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the program celebrates those who are building and leading successful, growing, and dynamic businesses.


'/>"/>
SOURCE TEI Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Magellan Biosciences Announces Agreement with Bruker to Provide Microbiology Tools to Battle Drug Resistance
2. Magellan Biosciences and Miacom Diagnostics Team Up to Enable Faster, Easier Identification of Pathogens as Part of Magellans End-to-End Suite of Microbiology Products Designed to Streamline Lab Workflow and Enable Better Treatment Decisions
3. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
4. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
5. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
6. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
7. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
8. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
9. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
10. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
11. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
(Date:12/8/2016)... Dec. 8, 2016 Soligenix, Inc. (OTCQB: SNGX) ... on developing and commercializing products to treat rare diseases ... that it will be hosting an Investor Webcast Event ... the origins of innate defense regulators (IDRs) as a ... oral mucositis and the recently announced and published Phase ...
(Date:12/8/2016)... to fuel Philadelphia,s innovative digital ... Southeastern Pennsylvania (" Ben Franklin "); Independence ... Cross; and Safeguard Scientifics ("Safeguard") (NYSE: SFE ... funding initiative over a four year period to grow ... burgeoning economic vitality in digital health, Ben Franklin ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):